S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Media

Cramer’s Non-Pharma Healthcare Pick

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

On tonight’s MAD MONEY on CNBC, Jim Cramer said he has a defensive play that will cover you in a couple places.  Cramer was resuming his non-pharmaceutical healthcare stock sector.  He wants to review the drug-coated stents and the pick he has is Volcano Corp (VOLC).  He doesn’t really want you to buy it until next week.  As of the market close it had a $625 million market cap; it makes intraveneous catheters that allow for exploration of arteries in place of angiograms.  Because of the problems with drug coated stents the doctors are needing to look closer at arteries inside rather than using imaging.

On a call-in, Cramer was asked about Syneron (ELOS-NASDAQ).  Cramer likes the P&G (PG) deal with the company.  He liked it lower and then said to sell it, but he likes it again at lower prices.  In another call-in, he was asked about Stereotaxis (STXS) on how much competition it could really give Hansen Medical and Cramer didn’t think it would be that much.

Jon C. Ogg
March 15, 2007

Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk
David Beren |

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk
3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026
Don Lair |

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026

Continue Reading

Douglas A. McIntyre |

As Stent Business Falls Apart, Field Gets More Crowded

Medtronic (MDT) got the FDA to approve its new drug-coated stent called the Endeavor. The agency did have some concerns…
Douglas A. McIntyre |

For Boston Scientific And JNJ, The Stent Stats Get Worse

"William O’Neill, dean of clinical affairs at University of Miami’sMiller School of Medicine, says stent-patient traffic is beginning topick up…
Douglas A. McIntyre |

Recapping Cramer’s Calls From Tuesday DEC 5, 2006

Yesterday, Jim Cramer had a fairly busy day on the markets. He noted that now Sirius (SIRI) really needs to…
Douglas A. McIntyre |

Boston Scientific (BSX): The Stent Business Can’t Get More Confused

After reports last week that drug-coated stents posed little risk to heart patients, a new survey shows that  "patients given…
Douglas A. McIntyre |

As Doctors Renew Interest In Stents, Boston Scientific (BSX) May Get A Break

Several studies which showed that stents could cause blood clotting in the heart have done significant damage to the revenue…
Douglas A. McIntyre |

Stent Safety Issues at the FDA….Hogwash

Stock Tickers: BSX, JNJ, ANPI, SRDX, CONR, BMY, SNY, ABT, MDT The FDA review of stents should not change the…
Douglas A. McIntyre |

Setbacks Back At Boston Scientific (BSX)

Boston Scientific (BSX) has been the "gang who couldn’t shot straight" of the medical device business for some time. It…
Douglas A. McIntyre |

Send The Stents To Europe, They’ll Try Anything

Boston Scientific (BSX) is beginning to market its new drug-coated stent in Europe. After the firestorm of criticism in the…
Douglas A. McIntyre |

Boston Scientific Tries To Save It Bacon

Problems with drug-coated stents have been blamed for blood vessel blockages and clotting. Several studies showing potential dangers from implanting…

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618